{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To determine the efficacy of related or unrelated allogeneic PBSC transplantation (PBSCT) using a preparative regimen of busulfan, melphalan and alemtuzumab, as measured by durable donor lymphohematopoietic cell engraftment. The primary efficacy endpoint is the presence of donor lymphohematopoietic chimerism (defined as at least 50% donor cells in the peripheral blood) in peripheral blood by day +100 (i.e., 100 days after allogeneic PBSCT).","groups":[{"description":"Three drug regimen using busulfan, and melphalan, and alemtuzumab.\n\nBusulfan, and melphalan, and alemtuzumab: intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).\n\nIntravenous melphalan 100 mg/m2 on day -3.\n\nIntravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.","id":"OG000","title":"Busulfan, and Melphalan, and Alemtuzumab"}],"populationDescription":"Data were collected but could not be analyzed. PI for this study has retired and any data that were gathered, are lost. No data are available for this assessment","reportingStatus":"POSTED","timeFrame":"Day +100","title":"Number of Participants With Presence of Donor Lymphohematopoietic Chimerism (Defined as at Least 50% Donor Cells in the Peripheral Blood) in Peripheral Blood by Day +100 (i.e., 100 Days After Allogeneic PBSCT).","type":"PRIMARY"}